Evidence / Senekowitsch et al. · 2023

Following spermidine metabolites after oral dosing

Selected research. Study type, product relevance and limitations are shown separately.

Editorial study summary

Study type: Triple-blind placebo-controlled crossover PK/metabolomic study
Product relevance: Indirect relevance; different dose/formulation
Sample or population: 12 healthy volunteers
Studied dose: Spermidine 15 mg/day
Duration: Two 5-day periods; 9-day washout
Finding: Plasma spermine increased, while plasma spermidine did not; salivary polyamines did not change.
Limitations: Short exposure and circulating measurements cannot establish long-term outcomes, tissue exposure or that every lower-dose supplement is ineffective. Different dose; no EGT combination.
Study quality: Original PMC design, results and disclosures checked. No formal overall risk-of-bias rating assigned.
Funding and disclosures: Authors report no external funding and no conflicts.

This research does not establish results for a DR.MORGAN finished product.